Interview, Fireside Chat
Researching Psilocybin's Effects on Depression - Dr. Rosalind Watts
- Psilocybin research is resurging after a decline following illegality, with activity restarting around 2006, driven by historical positive findings from the 1950s–1970s and the ability of psychedelics to disrupt fixed patterns of negative thinking and increase brain connectivity.
- A UK clinical study involving 20 individuals with treatment-resistant depression utilized low (10 mg) and high (25 mg) psilocybin doses, though the team faced constraints due to limited supply of Good Manufacturing Practice (GMP) psilocybin from a few providers.
- Therapeutic effects from the study generally persisted for two to three months before depression returned, with relapse occurring around the one-year mark for the majority of participants who remained well after six months, attributed to a lack of integration sessions.
- Current market conditions show high demand for antidepressants in the UK (64.7 million prescriptions last year) where standard treatments often fail to resolve root causes or cause long-term worsening, contrasting with the potential of psychedelics to offer rapid pattern-breaking.
- Future research plans include a comparative study of psilocybin versus antidepressants, requiring the team to refrain from offering sessions to previous participants to ensure the validity of the new trial.
- Long-term maintenance of benefits may require ongoing sessions every six months or access to alternative legal venues in Europe and South America, as well as community support and self-care practices like breathwork or meditation.
- Significant logistical and financial hurdles remain, including the difficulty of accessing GMP psilocybin, the high cost of setting up legal infrastructure, and the physical severity of withdrawal from existing antidepressants.
- Alternative access to altered states is possible through non-drug methods such as holotropic breathwork and deep meditation, which are noted to quiet the default mode network and ego structures similarly to psychedelics.
- The speaker envisions a future where psychedelics are viewed as a journey for deep self-understanding, potentially used periodically for life transitions, though long-term efficacy data remains uncertain and unpredictable personal goals may arise post-session.